Outsourcing-Pharma presents its weekly round-up of the latest new rungs on the pharmaceutical career ladder, including news from Icon, ACM, and Penn Pharma.
Craig Collingwood has joined UK-based Penn Pharma as director of finance.
The CDMO (contract development and manufacturing organisation) says he will play a big part in its latest growth plans, which kicked off with a £14m ($21.9m) investment in its South Wales specialist high containment facility.
Previously, Collingwood ran his own consultancy firm aimed at the pharma industry, and worked in finance for Catalent and Cardinal Health amongst others.
Of his new role, he said: “The future plans and growth targets at Penn really appealed to me, I am excited to have joined the team at such a significant point in the company’s development.
“Finance is particularly important in this transitional period so I can really use my skills to ensure strong cash management during the investment in our high containment operations.”
Icon has expanded its risk management as well as its early phase development leadership teams.
Susan Anton has become the director of epidemiology and risk management for the Irish CRO’s (contract research organisation) late phase and outcomes sector.
She joins the firm from Boehringer Ingelheim, where she was director of US medical outcomes research and registries.
And former Phase I clinical research physician Pui Leung becomes senior clinical research physician for Icon’s development solutions.
ACM Global Central Lab has named Isabel Struik head of business development in Europe.
Previously director of business development at CROMSOURCE, she will be responsible for developing the company’s development on the continent.
Angela Panzarella, president of the firm, said: “Isabel has extensive business development experience in the clinical trials industry and a thorough understanding of the logistics and challenges involved when it comes to central lab activities in clinical research.”
Market reseach firm CMI has drafted in two new members of its client solutions team.
Valerie Deaton joins as qualitative manager, where she will inform client decisions in a bid to improve business results.
Formerly a consumer researcher for firms like Coca-Cola and McDonald’s, Bill Douglas will become an account manager .
"Bill and Valerie are wonderful additions to our client solutions team," said Donna Wydra, senior vice president of client solutions for CMI. "They each possess a wide range of experience turning insights into action, particularly since they've spent years on both the client and supplier sides of the business."
DPT Laboratories has named Jeanette Riedle has been named senior director of continuous improvement.
In her new role, she will drive the firm’s developments in quality systems.
Rick Bentzinger, VP of human resources, said: "These initiatives will play a critical role in maintaining DPT's position as the leading provider of pharmaceutical development and manufacturing services for semi-solid and liquid products, and in expanding our position in the sterile and specialty products market."
Riedle was previously VP of global business transformation programs at KCI.
Gary Barnette has been hired as VP of drug development for Camargo Pharmaceutical Services.
The firm says it will leverage Barnette’s knowledge of US Food and Drug Administration (FDA) regulations, gained from years of experience in senior clinical research roles, such as for GTx.
He has also been a member of several joint drug development committees with industry leaders Merck, Orion, Johnson & Johnson and Ipsen.
Ken Phelps, Camargo President and CEO, said: "His extensive experience within regulatory affairs is important as Camargo looks toward the future growth of the company."